{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:21:16Z","timestamp":1773832876744,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03478-z","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:00:49Z","timestamp":1769598049000},"page":"1290-1307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007\u20132020"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-7633","authenticated-orcid":false,"given":"Himani","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4879-4770","authenticated-orcid":false,"given":"Ashwini","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-4395","authenticated-orcid":false,"given":"Yu-Han","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danmeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Odonkor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"13","key":"3478_CR1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385(13):1207\u201318.","journal-title":"N Engl J Med"},{"issue":"12","key":"3478_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145039","volume":"10","author":"E Taioli","year":"2015","unstructured":"Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. PLoS ONE. 2015;10(12):e0145039.","journal-title":"PLoS ONE"},{"key":"3478_CR3","unstructured":"American Cancer Society. Key statistics about mesothelioma. https:\/\/www.cancer.org\/cancer\/malignant-mesothelioma\/about\/key-statistics.html. Accessed November 5 2025."},{"issue":"8","key":"3478_CR4","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO-24-02425","volume":"43","author":"HL Kindler","year":"2025","unstructured":"Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of pleural mesothelioma: ASCO guideline update. J Clin Oncol. 2025;43(8):1006\u201338.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3478_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2023.06.011","volume":"18","author":"I Opitz","year":"2023","unstructured":"Opitz I, Bille A, Dafni U, et al. European epidemiology of pleural mesothelioma--real-life data from a joint analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database. J Thorac Oncol. 2023;18(9):1233\u201347.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3478_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","volume":"11","author":"A Bille","year":"2016","unstructured":"Bille A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11(2):249\u201355.","journal-title":"J Thorac Oncol"},{"key":"3478_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CLEP.S105396","volume":"8","author":"JL Beebe-Dimmer","year":"2016","unstructured":"Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743\u201350.","journal-title":"Clin Epidemiol"},{"issue":"18","key":"3478_CR8","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.3390\/cells11182924","volume":"11","author":"UAK Saddozai","year":"2022","unstructured":"Saddozai UAK, Wang F, Khattak S, et al. Define the two molecular subtypes of epithelioid malignant pleural mesothelioma. Cells. 2022;11(18):2924.","journal-title":"Cells"},{"issue":"7","key":"3478_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756\u201363.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3478_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","volume":"3","author":"P Taylor","year":"2008","unstructured":"Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008;3(7):764\u201371.","journal-title":"J Thorac Oncol"},{"issue":"14","key":"3478_CR11","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"28","key":"3478_CR12","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP van Meerbeeck","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881\u20139.","journal-title":"J Clin Oncol"},{"key":"3478_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1158416","volume":"13","author":"MG Mastromarino","year":"2023","unstructured":"Mastromarino MG, Aprile V, Lucchi M. Editorial: advances in malignant pleural mesothelioma: diagnosis, treatment, and molecular mechanisms. Front Oncol. 2023;13:1158416.","journal-title":"Front Oncol"},{"issue":"10272","key":"3478_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386.","journal-title":"Lancet"},{"issue":"10419","key":"3478_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295\u2013306.","journal-title":"Lancet"},{"issue":"2","key":"3478_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/oemed-2022-108706","volume":"80","author":"L Kurth","year":"2023","unstructured":"Kurth L, Mazurek JM, Blackley DJ. Malignant mesothelioma among US Medicare beneficiaries: incidence, prevalence and therapy, 2016\u20132019. Occup Environ Med. 2023;80(2):86\u201392.","journal-title":"Occup Environ Med"},{"key":"3478_CR17","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Surveillance Research Program. https:\/\/seer.cancer.gov\/about\/factsheets\/SEER_Overview.pdf. Accessed November 5 2025."},{"key":"3478_CR18","unstructured":"Surveillance Epidemiology and End Results (SEER) Program, National Cancer Institute (NCI). SEER-Medicare Linked Resource. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/ Accessed November 5 2025."},{"key":"3478_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103335","volume":"100","author":"W Meng","year":"2019","unstructured":"Meng W, Ou W, Chandwani S, Chen X, Black W, Cai Z. Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer. J Biomed Inform. 2019;100:103335.","journal-title":"J Biomed Inform"},{"issue":"9","key":"3478_CR20","volume":"5","author":"MD Danese","year":"2022","unstructured":"Danese MD, Daumont M, Nwokeji E, Gleeson M, Penrod JR, Lubeck D. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: analyses of Surveillance, Epidemiology, and End Results-Medicare data. Cancer Rep. 2022;5(9):e1568.","journal-title":"Cancer Rep"},{"issue":"1","key":"3478_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jso.27243","volume":"128","author":"E Taioli","year":"2023","unstructured":"Taioli E, Wolf A, Alpert N, Rosenthal D, Flores R. Malignant pleural mesothelioma characteristics and outcomes: a SEER-Medicare analysis. J Surg Oncol. 2023;128(1):134\u201341.","journal-title":"J Surg Oncol"},{"issue":"19","key":"3478_CR22","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.2217\/fon-2021-0047","volume":"17","author":"DM Waterhouse","year":"2021","unstructured":"Waterhouse DM, Nwokeji ED, Boyd M, et al. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting. Future Oncol. 2021;17(19):2439\u201348.","journal-title":"Future Oncol"},{"key":"3478_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1186\/s12885-015-1881-x","volume":"15","author":"C Raynaud","year":"2015","unstructured":"Raynaud C, Greillier L, Mazieres J, et al. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer. 2015;15:857.","journal-title":"BMC Cancer"},{"issue":"4","key":"3478_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/cam4.1378","volume":"7","author":"C Chouaid","year":"2018","unstructured":"Chouaid C, Assie JB, Andujar P, et al. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. Cancer Med. 2018;7(4):1102\u20139.","journal-title":"Cancer Med"},{"issue":"1","key":"3478_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-022-09750-7","volume":"22","author":"A Moore","year":"2022","unstructured":"Moore A, Bennett B, Taylor-Stokes G, McDonald L, Daumont MJ. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe. BMC Cancer. 2022;22(1):693.","journal-title":"BMC Cancer"},{"key":"3478_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2340\/1651-226X.2024.34802","volume":"63","author":"JB Sorensen","year":"2024","unstructured":"Sorensen JB, Baas P, Szepligeti SK, et al. Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study. Acta Oncol. 2024;63:649\u201357.","journal-title":"Acta Oncol"},{"issue":"2","key":"3478_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","volume":"20","author":"PM Forde","year":"2019","unstructured":"Forde PM, Scherpereel A, Tsao AS. Use of immune checkpoint inhibitors in mesothelioma. Curr Treat Options Oncol. 2019;20(2):18.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"3478_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cpt.2453","volume":"111","author":"DR Rivera","year":"2022","unstructured":"Rivera DR, Henk HJ, Garrett-Mayer E, et al. The friends of Cancer Research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies. Clin Pharmacol Ther. 2022;111(1):283\u201392.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3478_CR29","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.cllc.2021.08.003","volume":"23","author":"S Schmid","year":"2022","unstructured":"Schmid S, Zhan L, Dietrich K, et al. Treatment patterns and outcomes of patients with advanced pleural mesothelioma at an academic referral centre. Clin Lung Cancer. 2022;23(1):e43\u201353.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"3478_CR30","volume":"3","author":"K Kerrigan","year":"2022","unstructured":"Kerrigan K, Jo Y, Chipman J, et al. A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern. JTO Clin Res Rep. 2022;3(3):100280.","journal-title":"JTO Clin Res Rep"},{"issue":"8","key":"3478_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046456","volume":"11","author":"P Ferrante","year":"2021","unstructured":"Ferrante P. Hospitalisation costs of malignant mesothelioma: results from the Italian hospital discharge registry (2001\u20132018). BMJ Open. 2021;11(8):e046456.","journal-title":"BMJ Open"},{"issue":"55","key":"3478_CR32","first-page":"3","volume":"2020","author":"L Enewold","year":"2020","unstructured":"Enewold L, Parsons H, Zhao L, et al. Updated overview of the SEER-Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr. 2020;2020(55):3\u201313.","journal-title":"J Natl Cancer Inst Monogr"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03478-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:30:36Z","timestamp":1773822636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03478-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3478"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03478-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Himani Aggarwal is a full-time employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and holds stock of Merck & Co., Inc., Rahway, NJ, USA, and of Eli Lilly. Ashwini Arunachalam, Jae Min, Yu-Han Kao, Haidong Feng, and Danmeng Huang are full-time employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and hold stock of Merck & Co., Inc., Rahway, NJ, USA. Gloria Odonkor worked as a Merck & Co., Inc., Rahway, NJ, USA\u00a0Outcomes Research, Lung Cancer Co-op (a 6-month paid position) during the study and is currently a PhD candidate in Pharmaceutical Health Outcomes at the University of Texas at Austin; she has no other conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The deidentified data used in this study were limited and complied with the Health Insurance Portability and Accountability Act and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}